Domainex has been named the winner of the Innovation in Enabling Biotechnology Award at the 2007 UK BioEntrepreneurial Company of the Year Awards, presented by UK Trade and Investment in London
Domainex is a contract research organisation offering technology to solve expression of intractable gene targets and high quality computational and medicinal chemistry and is also a newly emerging drug discovery company.
More than 180 industry leaders attended the annual ceremony, which recognises innovation and entrepreneurship in the biotechnology industry.
Dr Renos Savva, one of the company's founders and the chief executive officer of Domainex, Dr Eddy Littler, received the award from Andrew Cahn, chief executive officer of UK Trade and Investment.
"We are delighted to have been presented with this award, which recognises our commitment to developing new technologies for streamlining and accelerating the drug discovery process", said Dr Savva.
Domainex has developed a high-throughput technology for producing soluble and stable protein fragments that are suitable for compound screening, structural biology studies or antibody production.
The approach resolves the discovery 'gap' that exists between the vast amount of genomic information that is now available, and the accessibility of the corresponding proteins for use in target validation and drug discovery.
Dr Keith Powell, chairman of Domainex, added, "We are a young, fast growing London company, capable of reaching drug targets that were previously impossible to reach - and we are now in a position to move from drug target identification into drug development".
